EZH2 and liver cancer: Recently, it was demonstrated that miR-101 represses HCC progression by directly targeting the enhancer of zeste homolog 2 (drosophila) (EZH2) oncogene and sensitizes liver cancer cells to chemotherapeutic treatment (58).